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Minimally invasive surgery, which has been extensively used 
to treat gastric adenocarcinoma, is now regarded as one of 
the standard treatments for early gastric cancer, and its suit-
ability for advanced gastric cancer is being investigated. The 
use of cutting-edge techniques for minimally invasive surgery 
enables surgeons to deliver various treatment options to 
minimize a patient’s distress and to maintain oncologic safe-
ty. Ongoing multicenter prospective studies aim to validate 
the efficacy of these surgical techniques and to expand the 
indications of minimally invasive surgery for the treatment of 
gastric cancer. In this review, we summarize the current sta-
tus and issues regarding minimally invasive surgery for the 
treatment of gastric cancer. (Gut Liver 2014;8:229-236)
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INTRODUCTION
Minimally invasive surgery (MIS) for gastric cancer has 
gained popularity because it provides better short-term (e.g., re-
duced pain) and long-term (e.g., increased quality of life) results. 
A minimally invasive approach for the treatment of early gastric 
cancer (EGC) is a safe and efficient alternative to open gastrec-
tomy.1 The proportion of patients treated using this approach 
is relatively smaller than the proportion of patients with EGC. 
However, surgeons experienced in minimally invasive gastrec-
tomy techniques have suggested that they could be successfully 
applied to the treatment of advanced gastric cancer (AGC).2-8
To overcome technical difficulties, and to achieve more 
precise and effective procedures, surgeons are enthusiastically 
adopting emerging techniques and instruments. Advanced and 
improved techniques enable surgeons to endeavor to expand 
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their indications to various types of surgical options that pro-
vide faster recovery and decrease distress after gastrectomy, 
while also preserving oncologic safety. In this article, we de-
scribed the current status, issues of debate, and future perspec-
tives regarding MIS for the treatment of gastric cancer.
INDICATION OF MIS FOR GASTRIC CANCER
The generally accepted indication of MIS for gastric cancer is 
that the patient has a clinical diagnosis of EGC without evidence 
of lymph node (LN) metastasis, except those who have lesions 
suitable for endoscopic treatment. The expanded criteria for 
endoscopic procedures have created some questions about when 
a patient should be treated using endoscopy or MIS.9-11 In any 
case, it is obvious that the role of wedge resection for EGC has 
been decreased due to widespread use of endoscopic approach.12 
We must first reach a consensus regarding the objective risk 
rate of recurrence or LN metastasis compared to the results from 
conventional surgery, which often require additional surgical 
resection (including LN dissection) after the endoscopic ap-
proach is used. Determining how to increase the accuracy of the 
preoperative diagnosis is also crucial.
Clinical T1 cancer with perigastric LN involvement and 
serosa-negative gastric cancer without LN metastasis are also 
regarded as expanded indications for the use of MIS.4,5,13,14 These 
specific groups of patients could be treated in randomized con-
trolled trials comparing different approaches. Discussions about 
MIS generally focus on the technical aspects. However, inac-
curate preoperative staging and a subsequent limited extent of 
surgery is an important issue. Many studies have shown that 
MIS does not increase peritoneal seeding or port site metastasis, 
even when used in cases of AGC.3,15-19
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MIS FOR EARLY GASTRIC CANCER
Multicenter prospective randomized clinical trials (RCTs) are 
awaiting the final results to confirm the oncologic safety of 
laparoscopic surgery for gastric cancer. However, the role of 
MIS for EGC is obvious and is widely accepted, especially in 
East Asia. The results of several RCTs have revealed the feasibil-
ity and safety of MIS for EGC.1,17,20-23 The results of recent meta-
analyses indicated that laparoscopic distal gastrectomy is a safe 
alternative to open conventional surgery. Complication rates 
are lower, there is less blood loss, hospital stays are shorter, and 
quality of life increases without compromising long-term out-
comes.24,25 However, the number of retrieved LNs was slightly 
fewer and the surgery time was longer.
We anticipate similar results from the ongoing multicenter 
RCTs in Korea and Japan (Korean Laparoscopic Gastrointestinal 
Surgery Study [KLASS] 01 trials and Japan Clinical Oncology 
Group [JCOG] 0912 trials). After the benefits of MIS are con-
firmed in these studies, laparoscopic surgery for EGC could be 
recognized, not as an investigational approach, but as a stan-
dard procedure in clinical practice. With the accumulated and 
extensive experiences and improved surgical instruments, some 
surgeons are now focusing on reducing the patient’s distress by 
using reduced ports or a single incision approach for EGC.26,27 
Extracorporeal anastomoses using minilaparotomy is being 
replaced by intracorporeal anastomoses and results in a totally 
laparoscopic gastrectomy.28-32 Several meta-analyses comparing 
laparoscopic distal gastrectomy versus open distal gastrectomy 
have consistently demonstrated that there is less blood loss, 
hospital stays are shorter, morbidity rates are lower, and postop-
erative mortality are similar, when laparosocpic surgery is used, 
although operative time is longer and there are fewer retrieved 
LN (Table 1).24,25,33-36 Improving the accuracy of the preoperative 
diagnosis is an important issue that must be resolved before this 
approach is used for AGC, because the numbers of cases that are 
actually AGC have been increasing as the use of this approach 
has become more prevalent.
MIS FOR AGC
Because of an inaccurate perioperative diagnosis, a significant 
number of patients with AGC have been treated using minimal-
ly invasive approaches.15 Therefore, the results of treating ad-
vanced cancer with MIS should be investigated. Although there 
is no evidence and there are no guidelines that indicate that the 
use of MIS is appropriate, even for EGC, experienced surgeons 
have begun to treat patients with AGC using MIS, and have 
reported acceptable short-term outcomes.2,4,5,15,37,38 For some 
selected AGC cases, surgeons believe that this approach is not 
inferior to open conventional surgery in terms of the oncologic 
aspects. In addition, laparoscopic manipulation under pneu-
moperitoneum was a putative risk factor for peritoneal seeding 
and port site metastasis, but is no longer clinically problematic. 
The technical difficulties involved in D2 LN dissection could be 
an important reason to negate MIS for AGC including serosa-
involved cancer. There are overwhelming technical difficulties 
to overcome if surgeons encounter large-size tumors or tumors 
that require multiorgan resection. Some experienced surgeons, 
however, can accurately perform D2 LN dissection with the cur-
rent instruments or surgical systems.
Experienced surgeons have reported oncologic outcomes of 
the use of MIS for AGC.4-6,15,17,37-40 MIS for locally advanced can-
cer has a similar survival rate compared to open conventional 
surgery. However, the sample sizes were too small to report on 
stage-specific survival rates. In our experience, even serosa-pos-
itive cancer (T4a) patients treated using MIS experienced similar 
survival and recurrence outcomes, compared to open surgery.15 
The results of a meta-analysis demonstrated that compared with 
open surgery, laparoscopic gastrectomy with D2 LN dissec-
tion had similar overall survival rates, comparable numbers of 
retrieved LNs, less blood loss, less pain, reduced postoperative 
complications, and shorter hospital stays.41 However, the re-
duced postoperative complication rate resulted from a decreased 
incidence of minor complications (e.g., wound infections and 
postoperative ileus), but the incidence of major complications 
was similar to open surgery.41 Recently, large-scale multicenter 
Table 1. Meta-Analysis of Laparoscopic versus Open Distal Gastrectomy for the Treatment of Gastric Cancer
Study Year Eligibility Procedure
No. of patients 
(LDG/ODG)
Operative  
time
Blood  
loss
No. of  
retrieved LN
Hospital  
stay
Morbidity Mortality
Memon et al.33 2008 4RCTs LDG/ODG 82/80 ODG LDG ODG Equivalent Equivalent Equivalent
Chen et al.34 2009 6RCTs LDG/ODG 323/306 ODG LDG ODG Equivalent LDG Equivalent
Kodera et al.35 2010 6RCTs LDG/ODG 343/323 ODG LDG ODG N/E LDG Equivalent
Ohtani et al.24 2011 5RCTs LDG/ODG 164/162 ODG LDG ODG LDG LDG Equivalent
Zorcolo et al.36 2011 6RCTs LDG/ODG 343/323 ODG LDG ODG Equivalent LDG Equivalent
Viñuela et al.25 2012 6RCTs/19NRCTs LDG/ODG 1,658/1,397 ODG LDG ODG LDG LDG Equivalent
The favored group for each value is shown.
LDG, laparoscopic distal gastrectomy; ODG, open distal gastrectomy; LN, lymph node; RCTs, randomized controlled trials; N/E, not evaluated; 
NRCTs, nonrandomized controlled trials. 
Son T, et al: Minimally Invasive Surgery for Gastric Cancer Treatment: Current Status and Future Perspectives  231
RCTs began enrollment of patients to assess the feasibility of 
MIS for AGC in Korea, Japan, and China (Table 2).
SENTINEL LN NAVIGATION SURGERY 
Sentinel node navigation surgery (SNNS) has been investigat-
ed for the purpose of increasing a patient’s quality of life while 
maintaining oncologic safety. However, the role of SNNS for 
gastric cancer remains to be elucidated, even though numerous 
investigations have been performed to increase the sensitivity of 
sentinel node (SN) detection.42 The accuracy of SN detection was 
approximately 90%.43,44 Sensitivity using isotope and dye simul-
taneously (dual tracer method) was greater than the sensitivity 
achieved when using any single tracer.43,45 However, results of 
a recent multicenter phase II trial in Japan indicated that high 
accuracy and detection rates were achieved when a dual tracer 
was used for small-sized stage T1 cancer.46 The SN detection 
rate was 97%, and 93% of SNs were positive among patients 
who had metastatic LNs. The authors concluded that dual tracer 
endoscopic injection using tin colloid and blue dye was a safe 
and feasible method for selected EGCs. To make the best thera-
peutic decision for patients, the accuracy of the preoperative 
diagnosis should be such that preoperatively underestimated pa-
tients would not be treated with SNNS.47 SNNS should be used 
with caution because of the presence of SNs at the level II LNs 
and a possibility of skip metastasis.44
In a study using porcine model, laparoscopic wedge resec-
tion or segmental resection with sentinel basin dissection was 
safe and achievable.48 In Korea, a phase III multicenter RCT 
(Sentinel Node Oriented Tailored Approach [SENORITA] trial, 
NCT01544413) for clinical stage IA cancer is comparing lapa-
roscopic SNNS to conventional laparoscopic gastrectomy.47 
Advanced minimally invasive techniques and the concepts 
underlying SNNS could contribute to changing current surgical 
practices for gastric cancer. So far, sentinel basin LN dissection 
and segmental or wedge resection of the stomach for small-
sized, T1N0M0 cancer could be a potential candidate for this 
approach.46,47
MIS FOR FUNCTION PRESERVATION
As the information about outcomes after the use of minimally 
invasive approaches has been accumulating, MIS has stimulated 
interest in function-preserving surgeries (e.g., pylorus-preserv-
ing gastrectomy, proximal gastrectomy). Initially, pylorus-pre-
serving gastrectomy (PPG) was a surgical option for gastric ul-
cers.49 This method, and other limited methods, provide a better 
quality of life and oncologic safety when used for selected types 
of gastric cancer.50-53 Advantages of pylorus-preserving gastrec-
tomy with gastrogastrostomy include less dumping syndrome, 
less bile reflux, less weight loss, and decreased gallstone forma-
tion.50,54-57 Because of the extremely small chance of macro- and 
micro-metastases at the LN stations of the supra- (#5) and infra-
pylroic (#6) areas, oncologic safety is thought to be guaranteed 
when the indication for this method is strictly limited to middle 
third cT1N0M0 cancer located more than 4 cm from the pylo-
rus.50,57,58 However, use of a laparoscopic approach for this pro-
cedure is difficult for inexperienced surgeons because it should 
Table 2. Multicenter, Prospective, Randomized Controlled Trials of Laparoscopic Gastrectomy for the Treatment of Advanced Gastric Cancer 
Trial KLASS 02 (NCT01456598) JLSSG 0901 (UMIN-CTR 000003420) CLASS 01 (NCT01609309)
Phase III II/III III
Intervention LDG vs ODG LDG vs ODG LDG vs ODG
Inclusion criteria cT2/cT3/cT4a cT2/cT3/cT4a cT2/cT3/cT4a
cN0-1 (including LN#7) cN0-2 (excluding bulky N2) cN0-3 (except bulky LNs)
Enrollment 1,050 500 1,056
Primary outcome 3-yr disease-free survival Incidence of anastomotic leakage or  
pancreatic fistula 
Relapse-free survival 
3-yr disease-free survival
Secondary  
outcome
Early postoperative complication 
Postoperative mortality
Late postoperative complication 
Postoperative recovery index 
Postoperative quality of life
3-yr overall survival
Overall survival 
Proportion of LDG completion 
Proportion of conversion to open  
surgery 
Adverse events 
Short-term clinical outcomes 
Number of retrieved LN 
Recurrence sites
Morbidity and mortality
3-yr overall survival
3-yr recurrence pattern 
Postoperative recovery course 
Inflammatory and immune re-
sponse
KLASS, Korean Laparoscopic Gastrointestinal Surgery Study; JLSSG, Japanese Laparoscopic Gastric Surgery Study Group; CLASS, Chinese Lapa-
roscopic Gastrointestinal Surgery Study; LDG, laparoscopic distal gastrectomy; ODG, open distal gastrectomy; LN, lymph node.
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preserve the pyloric and hepatic branches of the vagus nerve 
and infrapyloric vessels.50,58,59 The results of recent large-volume 
retrospective analyses indicated that compared to conventional 
laparoscopic distal gastrectomy, laparoscopic pylorus-preserving 
gastrectomy is oncologically safe, has a similar morbidity rate, 
does not result in decreased patient body fat and nutritional 
profiles, and has a lower incidence of gallstone formation.50 
Nonetheless, more RCTs that examine long-term outcomes and 
the incidence of gastric stasis should be performed before this 
procedure is widely adopted.
The results of laparoscopic proximal gastrectomy for upper 
third EGC have also been reported.52,53 The long-term results for 
patients who received a total gastrectomy were significantly 
worse compared with patients who received a partial gastrec-
tomy.60 The results of a recent multicenter retrospective com-
parison study among patients who underwent total gastrectomy 
versus proximal gastrectomy with esophagogastrostomy versus 
proximal gastrectomy with jejunal interposition indicated that 
proximal gastrectomy was superior to total gastrectomy with 
regard to postoperative nutritional status evaluated by serum 
albumin and hemoglobin, but not weight loss.61 Dumping syn-
drome and diarrhea were also decreased, but more patients re-
ported heartburn and a “stuck feeling.”61 Experienced surgeons 
have investigated, and reported on, various types of reconstruc-
tion methods and their technical feasibility after laparoscopic 
proximal gastrectomy.61-63 However, there is no consensus in 
the literature with regard to an ideal reconstruction method, and 
well-designed RCTs have not been performed. The number of 
EGC patients who are candidates for function-preserving sur-
geries has been increasing, and one of these surgical methods 
may be an useful option for these patients.
MIS FOR TECHNICALLY-DEMANDING PROCEDURES
Advanced technology has made possible the use of MIS for 
the above-mentioned procedures. Technically-demanding pro-
cedures such as total gastrectomy with or without splenectomy, 
gastrectomy with multivisceral resection, and completion total 
gastrectomy for remnant gastric cancer have been successfully 
performed by experienced surgeons using minimally invasive 
approaches.64-68 Single incision or reduced port surgery for 
gastric cancer also has been reported to be a safe and feasible 
procedure.26,27 Although this approach is safe and feasible, more 
evidence that demonstrates efficacy is needed. Procedures of 
this type are also exceedingly challenging for most surgeons. To 
overcome these obstacles, case-specific instruments, improved 
camera systems, and adequate training programs for novice 
surgeons should be developed. RCTs that indicate that these 
procedures are efficacious are also needed.
ROBOTIC SURGERY FOR GASTRIC CANCER
Surgical robotic systems have been introduced into the field 
of gastric cancer treatment as an improved technology that 
would overcome the technical limitations of laparoscopy.69-71 
Compared with conventional laparoscopic surgery, robotic sys-
tems provide more defined movements and a better operative 
view. Unlike other malignancies (e.g., lower rectal cancer, pros-
tate cancer), however, the role for these systems in the treatment 
of gastric cancer is unclear.70,72-74 Since 2005, a robotic system 
has been used for gastric cancer surgery in Korea, and many 
experienced MIS surgeons have reported that compared with 
laparoscopic gastrectomy, robotic gastrectomy is safe and ef-
fective.71,75-77 These results were achieved even though the early 
experience of robotic surgery was compared with laparoscopic 
surgery performed by experienced laparoscopic surgeons.
Results of a meta-analysis revealed that compared with 
laparoscopic surgery, use of robotic surgery for gastric cancer 
significantly decreases intraoperative blood loss, and results 
in comparable morbidity and mortality.78 The use of robotic 
gastrectomy also resulted in significantly less blood loss and 
a shorter hospital stay compared with open surgery. However, 
the operative time  of robotic gastrectomy was significantly 
longer than the other two approaches. The current indications 
for robotic surgery are similar to laparoscopic surgery. Some 
investigators have suggested that the feasibility and advantages 
of robotic surgery for technically-challenging complicated cases 
(e.g., very advanced cancer, multiorgan resection, and function-
preserving surgeries) should be investigated.2,70,79
In Korea, a multicenter prospective observational study 
(Multi-institutional Study on the Assessment of Robotic Sur-
gery for Gastric Cancer, NCT01309256) that compares robotic 
and laparoscopic surgery for gastric cancer has begun to enroll 
patients. This study will investigate cost-effectiveness, patient 
quality of life, learning curve of the surgeon, and feasibility. The 
results of this study will contribute data that address questions 
about clinical indications for, and efficacy of, robotic surgery in 
the field of gastric cancer treatment. 
ONGOING MULTICENTER TRIALS OF MIS FOR GASTRIC 
CANCER TREATMENT
Many MIS surgeons have conducted prospective studies with 
a small number of patients in a single or a limited number of 
institutions. However, large-scale multicenter RCTs were re-
cently designed and performed, especially in Korea and Japan. 
In Japan, the results of phase II and phase III clinical trials con-
ducted by JCOG (JCOG0703 and JCOG0912 trials, respectively) 
have confirmed the safety. The results for long-term outcomes 
of laparoscopic surgery for stage I gastric cancer are pending. 
In Korea, a phase III, KLASS 01 trial completed patient enroll-
ment and is awaiting final results regarding oncologic safety 
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for use of MIS for clinical stage I gastric cancer. Results of an 
interim analysis of KLASS 01 trial revealed that there were no 
significance differences in morbidity and mortality outcomes 
between laparoscopic distal gastrectomy and open distal gas-
trectomy patients.23 Convinced that laparoscopic surgery is 
safe, the KLASS group has begun a multicenter phase III trial 
for locally advanced cancer (KLASS 02 trial, NCT01456598). 
The primary endpoint is noninferiority of 3-year disease-free 
survival for MIS compared to open conventional surgery. The 
Japanese Laparoscopic Gastric Surgery Study group (JLSSG) has 
also begun phase II and III trials (JLSSG0901 trial; UMIN-CTR 
number, 000003420) to investigate the technical and oncology 
safety of laparoscopy used for the treatment of AGC. A Chinese 
Laparoscopic Gastrointestinal Surgical Study Group (CLASS) 
trial recently initiated patient recruitment to compare the safety 
and oncologic feasibility of laparoscopic surgery for AGC. 
The primary endpoint under investigation is 3-year disease-
free survival (CLASS 01 trial, NCT01609309). A KLASS 03 
(NCT01584336) trial is in progress to investigate long-term out-
comes and feasibility and safety of the use of laparoscopic total 
gastrectomy for the treatment of stage I gastric cancer.12,80,81 In 
Korea, a multicenter observational study (Multi-institutional 
Study on the Assessment of Robotic Surgery for Gastric Cancer, 
NCT01309256) is comparing robotic and laparoscopic gastrec-
tomy for cost-effectiveness, quality of life, and feasibility. To 
examine the role of SNNS for the treatment of clinical stage 
IA gastric cancer, a phase III multicenter RCT (SENORITA trial, 
NCT01544413) is also in progress in Korea. These studies will 
reveal the real efficacy of MIS for gastric cancer and aid in the 
development of guidelines for surgeons.
CURRENT STATUS OF MIS FOR GASTRIC CANCER IN 
KOREA
In Korea, MIS has become a widely accepted treatment for 
EGC, and is performed as an alternative to conventional open 
surgery.82 Although the use of MIS is under investigation, sev-
eral large-volume centers have also expanded their clinical 
indications for the use of MIS for the treatment of AGC. More 
limited surgeries, such as proximal gastrectomy for upper gas-
tric cancer and pylorus-preserving gastrectomy, are actively ap-
plied and are performed with minimally invasive approaches.50,62 
The use of SNNS is being examined using a multicenter RCT 
that includes wedge or segmental resection of the stomach with 
sentinel basin LN dissection.47 Some surgeons have attempted 
to focus on less invasive surgery such as reduced port or single 
incision gastrectomy. However, it is debatable whether this type 
of approach has any real benefit for the patient (i.e., except a 
cosmetic advantage).26 Nonetheless, these approaches appear to 
be feasible and safe when performed by experienced surgeons 
using innovative techniques. Korea is one of the leading coun-
tries in the use of the newest robotic surgery technology for 
the treatment of gastric cancer. The benefits for the patient are 
debatable when the high cost is considered, but the technol-
ogy improves surgical outcomes for the treatment of malignant 
disease.46,71 Robotic surgery will have an appropriate role in 
the treatment of gastric cancer and could contribute to the 
expanding clinical indications of the use of MIS for the treat-
ment of gastric cancer. The role of the gastric surgeon in Korea 
is increasing as the incidence of gastric cancer is still high, and 
the number of large-volume centers with experienced surgeons 
have increased.82 Thanks to the vigorous efforts of many gastric 
surgeons in Korea, many well-designed studies are being per-
formed and their results are pending. The surgical methods and 
techniques are being extensively shared and are contributing to 
the standardization of surgical treatments among institutions.
CONCLUSIONS
The use of MIS for the treatment of gastric cancer is evolving. 
The clinical indications are expanding to its use in function-
preserving surgery and in more extensive surgeries. Technical 
difficulties and lack of evidence have hindered rapid and wide-
spread use of MIS for gastric cancer, but it seems to be promis-
ing approach. The results of the many well-designed studies that 
are in progress are expected to indicate that MIS is as safe and 
effective as open conventional surgery.
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